HCV Treatment
Gilead's Sofosbuvir + Velpatasvir Combo Shows Good Results in Phase 3 Trials
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 25 September 2015 00:00
- Written by Gilead Sciences
A dual combination of Gilead Sciences' sofosbuvir (Sovaldi) and new pangenotypic HCV NS5A inhibitor velpatasvir (GS-5816) taken for 12 weeks produced cure rates of 95% to 100% for people with hepatitis C genotypes 1 through 6, including patients with compensated liver cirrhosis, in the ASTRAL trials, the company announced this week. People with decompensated cirrhosis, however, did better when they added ribavirin.
ICAAC 2015: New Hepatitis C NS5A Inhibitor Looks Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 25 September 2015 00:00
- Written by Liz Highleyman
A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta -- EDP-239 -- was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego.
IAS 2015: International AIDS Society Conference Starts this Weekend in Vancouver
- Details
- Category: HIV Treatment
- Published on Wednesday, 15 July 2015 00:00
- Written by HIVandHepatitis.com
The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) starts this Sunday and runs July 19-22 in Vancouver. HIV prevention -- including treatment-as-prevention and pre-exposure prophylaxis (PrEP) -- will be a major focus of the meeting. Other topics will include antiretroviral drugs in development, expanding access to treatment and retention in care, and HIV/hepatitis coinfection. HIVandHepatitis.com will be on site covering the latest news.
Technivie Regimen Shows Good Response Rate for People with HCV Genotype 4
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 August 2015 00:00
- Written by Liz Highleyman
An interferon-free combination of paritaprevir, ritonavir, and ombitasvir -- the drugs in AbbVie's recently approved Technivie coformulation -- taken for 12 weeks cured more than 90% of patients with hepatitis C virus (HCV) genotype 4 in the PEARL-I trial, according to a study report in the June 20 edition of The Lancet.
FDA Approves Daclatasvir for Hepatitis C Genotype 3, Technivie for Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 15 July 2015 00:00
- Written by HIVandHepatitis.com
The U.S. Food and Drug Administration has approved 2 new treatments for hepatitis C virus (HCV) genotypes 3 and 4, which account for millions of cases worldwide. Daclatasvir (Daklinza) received the nod for use in combination with sofosbuvir (Sovaldi) for hard-to-treat genotype 3, while AbbVie received approval for its 2D paritaprevir/ritonavir/ombitasvir coformulation for genotype 4. Options remain limited, however, for people with liver cirrhosis.
Web Design and Development by